Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-6 Sublingual Tablet in Acute Ischemic Stroke Undergoing Endovascular Therapy
CTR20233367Phase 2Completed
- Sponsor
- Nanjing NeuroDawn Pharmaceutical
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Y-6 sublingual tablet + cilostazol with Y-6 placebo + cilostazol placebo (2 arms). Primary endpoint: Proportion of subjects with mRS 0–1 at 90±7 days after randomization. Started Nov 2023; status: completed.
02
Drugs
cilostazol + dexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20233367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233367.